Summary
LN 5330 is a new benzothiadiazine which is a structural analogue of diazoxide. Its effects in vivo were studied on blood glucose levels and insulin, glucagon and somatostatin secretion in normal dogs, and in vitro on glucagon and insulin secretion from the isolated perfused rat pancreas. The results were compared with those obtained with diazoxide at equimolar dose or concentration. In the normal anaesthetized dog having a T-shaped catheter inserted in the pancreaticoduodenal vein, the infusion of LN 5330 (87.8 μmol/kg for 20 min) induced (1) a progressive increase in blood glucose levels, (2) a rapid decrease in insulin and somatostatin output rate, (3) an immediate increase in pancreatic glucagon secretion, and (4) a delayed decrease of arterial blood pressure. The equimolar dose of diazoxide provoked the same effects on blood glucose levels, insulin and somatostatin output, but a marked decrease in glucagon output and in arterial blood pressure. In the isolated rat pancreas perfused with 8.3 mmol/l glucose, the infusion of LN 5330 (440 μmol/l for 30 min) induced a drastic fall in insulin and a rapid and persistent increase in glucagon output. This stimulatory effect on glucagon secretion was not found with diazoxide at equimolar concentration. These findings show that LN 5330 is a substance which is distinct from diazoxide and interesting because of its double action: inhibition of insulin secretion and stimulation of glucagon secretion.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Blayac JP, Ribes G, Buys D, Puech R, Loubatières-Mariani MM (1981) Effects of a new benzothiadiazine derivative, LN 5330 on insulin secretion. Arch Int Pharm Therap 253: 154–163
Loubatières A, Mariani MM, De Malbosc H, Ribes G, Chapal J (1969) Etude expérimentale d'un nouveau sulfamide hypoglycémiant particulièrement actif, le HB 419 ou glibenclamide. I. Action bêtacytotrope et insulino-sécrétrice. Diabetologia 5: 1–10
Alric R, Mariani MM, Loubatières A (1965) Importance de l'état des éléments figurés du sang et en particulier de celui des globules rouges sur les valeurs du glucose sanguin mesuré par l'autoanalyseur Technicon. Path Biol 13: 506–511
Hales CN, Randle PJ (1963) Immunoassay of insulin with insulin antibody precipitate. Biochem J 68: 137–146
Unger RH, Aguilar-Parada E, Müller W, Eisentraut AM (1970) Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49: 837–848
Ribes G, Trimble ER, Blayac JP, Wollheim CB, Puech R, Loubatières-Mariani MM (1981) Effect of a new hypoglycaemic agent (HB 699) on the in vivo secretion of pancreatic hormones in the dog. Diabetologia 20: 501–505
Zar JH (1974) Biostatistical Analysis. Prentice Hall, Englewood Cliffs, New Jersey, USA, p 151
Loubatières A, Mariani MM, Alric R (1968) The action of diazoxide on insulin secretion, medulloadrenal secretion and the liberation of catecholamines. Ann NY Acad Sci 150: 226–241
Samols E, Harrison J (1975) Suppression of glucagon secretion by diazoxide. Clin Res 23: 330 (Abstract)
Altszuler N, Hampshire J, Moraru E (1977) On the mechanism of diazoxide-induced hyperglycemia. Diabetes 26: 931–935
Urdanivia E, Pek S, Santiago JC (1979) Inhibition of glucagon secretion by diazoxide in vitro. Diabetes 28: 26–31
Roe TF, Kogut MD (1982) Idiopathic leucine sensitive hypoglycemia syndrome: insulin and glucagon responses and effects of diazoxide. Pediatric Res 16: 1–4
Manteghetti M, Puech R, Ribes G, Blayac JP, Loubatières-Mariani MM (1984) Effect of LN 5330 on insulin release and calcium uptake by isolated rat islets of Langerhans. Comparison with diazoxide. Arch Int Pharmacodyn Ther (in press)
Leclercq-Meyer V, Rebolledo O, Marchand J, Malaisse WJ (1976) Glucagon release: paradoxical stimulation by glucose during calcium deprivation. Science 189: 897–899
Kawazu S, Ikeuchi M, Kikuchi M, Kanazawa Y, Fujimoto Y, Kosaka K (1981) Dual effects of veratridine on glucagon and insulin secretion. Diabetes 30: 446–450
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hillaire-Buys, D., Ribes, G., Blayac, J.P. et al. A new benzothiadiazine derivative, LN 5330: effects on pancreatic hormones. Diabetologia 27, 583–586 (1984). https://doi.org/10.1007/BF00276972
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00276972